Valuation: Vertex Pharmaceuticals Incorporated

Market Cap 139B 119B 111B 102B 191B 13,291B 194B 1,315B 513B 6,677B 522B 510B 22,083B P/E 2026 *
32.3x
P/E 2027 * 26.4x
Enterprise Value 123B 106B 98.77B 90.41B 170B 11,791B 172B 1,167B 455B 5,923B 463B 453B 19,591B EV / Sales 2026 *
9.34x
EV / Sales 2027 * 8.2x
Free-Float
99.79%
Yield 2026 *
-
Yield 2027 * -
1 day+1.44%
1 week+8.36%
Current month+14.87%
1 month+13.70%
3 months+26.41%
6 months+14.92%
Current year+20.89%
1 week 502.53
Extreme 502.53
555.32
1 month 465
Extreme 465
555.32
Current year 412.27
Extreme 412.27
555.32
1 year 374.17
Extreme 374.17
555.32
3 years 340.83
Extreme 340.83
555.32
5 years 176.36
Extreme 176.36
555.32
10 years 71.46
Extreme 71.46
555.32
Manager TitleAgeSince
Chief Executive Officer 53 01/04/2020
Director of Finance/CFO 57 10/04/2019
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 66 01/01/1998
Chairman 70 01/05/2012
Director/Board Member 57 18/06/2015
Date Insider Type Main position Quantity % Market Cap.
21/7/26 Free

General Counsel

8,251 0.0033%
21/7/26 Free

Public Communications Manager

8,251 0.0033%
15/7/26 Free

Director

100 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%+8.36%+37.89%+56.26% 139B
+0.88%+6.38%+76.86%+128.23% 1,119B
+1.07%+3.80%+51.03%+61.48% 651B
+1.20%+6.21%+26.47%+76.45% 468B
+1.02%+5.77%+43.09%+47.70% 374B
+0.85%+4.07%+23.88%+41.58% 302B
+1.26%+6.81%+1.59%+14.67% 259B
+1.88%+5.81%+48.54%+68.52% 238B
+1.59%+2.09%-15.52%-52.29% 208B
+1.87%+5.61%+25.81%+92.42% 181B
Average +1.31%+5.31%+31.97%+53.50% 393.88B
Weighted average by Cap. +1.15%+5.21%+44.08%+71.97%

Financials

2026 *2027 *
Net sales 13.2B 11.3B 10.58B 9.68B 18.17B 1,263B 18.41B 125B 48.73B 634B 49.55B 48.47B 2,098B 14.62B 12.52B 11.72B 10.73B 20.13B 1,399B 20.4B 138B 53.99B 703B 54.89B 53.7B 2,324B
Net income 4.31B 3.69B 3.45B 3.16B 5.93B 412B 6.01B 40.77B 15.9B 207B 16.17B 15.82B 684B 5.23B 4.48B 4.19B 3.84B 7.2B 500B 7.29B 49.51B 19.31B 251B 19.63B 19.2B 831B
Net Debt -15.68B -13.43B -12.56B -11.5B -21.58B -1,500B -21.87B -148B -57.89B -753B -58.86B -57.58B -2,492B -19.1B -16.36B -15.31B -14.01B -26.3B -1,828B -26.65B -181B -70.54B -918B -71.73B -70.17B -3,037B
Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (62.9%), Europe (28.8%) and other (8.3%).
Employees
6,400
Date Price Change Volume
21/08/26 US$548.05 +1.44% 1,074,914
20/08/26 US$540.26 -2.14% 1,062,465
19/08/26 US$552.06 +4.52% 1,437,713
18/08/26 US$528.19 +2.45% 1,497,081
17/08/26 US$515.55 +1.94% 1,111,401
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
548.05USD
Average target price
560.21USD
Spread / Average Target
+2.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VRTX Stock